ReduMixDTI:用特征冗余减少和可解释的注意力机制预测药物向相互作用
Mingqing Liu1,2, Xuechun Meng1,2, Yiyang Mao1,2
1National Engineering Laboratory for Brain-inspired Intelligence Technology and Application, School of Information Science and Technology, University of Science and Technology of China, Hefei 230026, Anhui, China.
Journal of chemical information and modeling
|November 21, 2024
概括
ReduMixDTI通过减少冗余特征和捕获复杂的结合相互作用来增强药物发现,以准确预测药物向相互作用. 这种可解释的模型可以在现实场景中提高预测性能.
科学领域:
- 计算化学是一种计算化学.
- 生物信息学是一种生物信息学.
- 药物发现 药物发现
背景情况:
- 准确的药物向相互作用 (DTI) 预测对于有效的药物发现至关重要.
- 目前用于DTI预测的深度学习模型由于整体表示和过于简单的交互建模而遭受特征冗余和噪声.
- 这限制了预测准确性和约束机制的解释性.
研究的目的:
- 开发一个端到端的深度学习模型,ReduMixDTI,解决特征冗余,并明确模拟复杂的本地交互,以改进DTI预测.
- 提高DTI预测模型的可解释性.
主要方法:
- 药物和目标特征分别使用图形神经网络 (GNN) 和卷积神经网络 (CNN) 来编码.
- 功能改进是从道和空间视角进行的.
- 使用注意力机制来建模药物和标子结构之间的双对相互作用.
主要成果:
- 在三个基准数据集和外部测试集上,ReduMixDTI显著优于七种最先进的方法.
- 除研究和蛋白质注意力重量的可视化证实了该模型的稳定性和可解释性.
- 该模型有效地减少了特征冗余,并捕捉了复杂的绑定相互作用.
结论:
- 通过解决现有的深度学习模型的局限性,ReduMixDTI为DTI预测提供了强大的和可解释的方法.
- 该模型能够减少特征冗余并捕获本地交互的能力,推动了DTI预测领域的发展.
- 这有助于更高效和有效的药物发现和开发管道.
相关概念视频
Drug-Receptor Interactions
5.0K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
5.0K
Quantitative Aspects of Drug-Receptor Interaction
934
The receptor occupancy theory connects a drug's response to the number of occupied receptors. With higher drug concentrations, more receptors are occupied, leading to increased responses. The formation of drug-receptor complexes involves association and dissociation rates, which reach equilibrium when the forward and backward reactions are equal. The equilibrium association constant (Ka) and its inverse, the equilibrium dissociation constant (Kd), indicate drug affinity. Higher Ka and lower...
934
Structure-Activity Relationships and Drug Design
595
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
595
Drug Discovery: Overview
7.5K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.5K
Drug-Receptor Interaction: Antagonist
2.7K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Antagonists can be classified as competitive or noncompetitive based on their...
2.7K
Protein-protein Interfaces
12.5K
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
12.5K


